Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Genetic Testing in Clinical Settings.

Franceschini N, Frick A, Kopp JB.

Am J Kidney Dis. 2018 Oct;72(4):569-581. doi: 10.1053/j.ajkd.2018.02.351. Epub 2018 Apr 11. Review.

PMID:
29655499
2.

The role of pharmacogenomics in adverse drug reactions.

Cacabelos R, Cacabelos N, Carril JC.

Expert Rev Clin Pharmacol. 2019 May;12(5):407-442. doi: 10.1080/17512433.2019.1597706. Epub 2019 Apr 24. Review.

PMID:
30916581
3.

Determining the effects and challenges of incorporating genetic testing into primary care management of hypertensive patients with African ancestry.

Horowitz CR, Abul-Husn NS, Ellis S, Ramos MA, Negron R, Suprun M, Zinberg RE, Sabin T, Hauser D, Calman N, Bagiella E, Bottinger EP.

Contemp Clin Trials. 2016 Mar;47:101-8. doi: 10.1016/j.cct.2015.12.020. Epub 2015 Dec 30.

4.

New approaches to molecular diagnosis.

Korf BR, Rehm HL.

JAMA. 2013 Apr 10;309(14):1511-21. doi: 10.1001/jama.2013.3239.

PMID:
23571590
5.

Facilitating clinical implementation of pharmacogenomics.

Mrazek DA, Lerman C.

JAMA. 2011 Jul 20;306(3):304-5. doi: 10.1001/jama.2011.1010. No abstract available.

6.

Genetic studies in chronic kidney disease: interpretation and clinical applicability.

Witasp A, Nordfors L, Carrero JJ, Luttropp K, Lindholm B, Schalling M, Stenvinkel P.

J Nephrol. 2012 Nov-Dec;25(6):851-64. doi: 10.5301/jn.5000216. Review.

PMID:
23042432
7.

Pharmacogenetics approach to therapeutics.

Koo SH, Lee EJ.

Clin Exp Pharmacol Physiol. 2006 May-Jun;33(5-6):525-32. Review.

PMID:
16700889
8.

Pharmacogenomics: bridging the gap between science and practice.

Lee KC, Ma JD, Kuo GM.

J Am Pharm Assoc (2003). 2010 Jan-Feb;50(1):e1-14; quiz e15-7. doi: 10.1331/JAPhA.2010.09124. Review.

PMID:
20368146
9.

Clinical association between pharmacogenomics and adverse drug reactions.

Zhou ZW, Chen XW, Sneed KB, Yang YX, Zhang X, He ZX, Chow K, Yang T, Duan W, Zhou SF.

Drugs. 2015 Apr;75(6):589-631. doi: 10.1007/s40265-015-0375-0. Review.

PMID:
25895462
10.

Role of pharmacogenomics in dialysis and transplantation.

Birdwell K.

Curr Opin Nephrol Hypertens. 2014 Nov;23(6):570-7. doi: 10.1097/MNH.0000000000000065.

11.

Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers.

Dunnenberger HM, Crews KR, Hoffman JM, Caudle KE, Broeckel U, Howard SC, Hunkler RJ, Klein TE, Evans WE, Relling MV.

Annu Rev Pharmacol Toxicol. 2015;55:89-106. doi: 10.1146/annurev-pharmtox-010814-124835. Epub 2014 Oct 2. Review.

12.

Genetic predisposition to adverse drug reactions in the intensive care unit.

Empey PE.

Crit Care Med. 2010 Jun;38(6 Suppl):S106-16. doi: 10.1097/CCM.0b013e3181de09f8. Review.

PMID:
20502164
13.

Personal genome testing: test characteristics to clarify the discourse on ethical, legal and societal issues.

Bunnik EM, Schermer MH, Janssens AC.

BMC Med Ethics. 2011 Jun 14;12:11. doi: 10.1186/1472-6939-12-11. Review.

14.

Attitudes of clinicians following large-scale pharmacogenomics implementation.

Peterson JF, Field JR, Shi Y, Schildcrout JS, Denny JC, McGregor TL, Van Driest SL, Pulley JM, Lubin IM, Laposata M, Roden DM, Clayton EW.

Pharmacogenomics J. 2016 Aug;16(4):393-8. doi: 10.1038/tpj.2015.57. Epub 2015 Aug 11.

15.

Pharmacogenomics, genetic tests, and patent-based incentives.

Meurer MJ.

Adv Genet. 2003;50:399-426; discussion 507-10.

PMID:
14714702
16.

Perception of the usefulness of drug/gene pairs and barriers for pharmacogenomics in Latin America.

Quinones LA, Lavanderos MA, Cayun JP, Garcia-Martin E, Agundez JA, Caceres DD, Roco AM, Morales JE, Herrera L, Encina G, Isaza CA, Redal MA, Larovere L, Soria NW, Eslava-Schmalbach J, Castaneda-Hernandez G, Lopez-Cortes A, Magno LA, Lopez M, Chiurillo MA, Rodeiro I, Castro de Guerra D, Teran E, Estevez-Carrizo F, Lares-Assef I.

Curr Drug Metab. 2014 Feb;15(2):202-8.

PMID:
24524664
17.

Advances in the Pharmacogenomics of Adverse Drug Reactions.

Collins SL, Carr DF, Pirmohamed M.

Drug Saf. 2016 Jan;39(1):15-27. doi: 10.1007/s40264-015-0367-8. Review.

PMID:
26650062
18.

Emerging ethical issues in pharmacogenomics: from research to clinical practice.

Freund CL, Wilfond BS.

Am J Pharmacogenomics. 2002;2(4):273-81. Review.

PMID:
12421098
19.

Health regulatory communications of well-established safety-related pharmacogenomics associations in six developed countries: an evaluation of alignment.

Tan-Koi WC, Lim ES, Teo YY.

Pharmacogenomics J. 2017 Mar;17(2):121-127. doi: 10.1038/tpj.2016.5. Epub 2016 Feb 23.

PMID:
26902540
20.

Physicians' pharmacogenomics information needs and seeking behavior: a study with case vignettes.

Heale BSE, Khalifa A, Stone BL, Nelson S, Del Fiol G.

BMC Med Inform Decis Mak. 2017 Aug 1;17(1):113. doi: 10.1186/s12911-017-0510-9.

Supplemental Content

Support Center